The RTS,S/AS01 Malaria Vaccine in Children 5 to 17 Months of Age at First Vaccination
This article, published in Expert Review of Vaccines, reviews the findings around the safety and feasibility of the RTS,S/AS01 vaccine in children at 5 to 17 months of age—an age category for which RTS,S/AS01 pilot implementation was recommended by the World Health Organization (WHO). The trial was conducted in seven sub-Saharan African countries and found that a four-dose schedule of RTS,S/AS01 was efficacious within the study population, providing the greatest impact against clinical and severe malaria. Further modeling found a significant number of severe malaria cases and deaths could be prevented by the vaccine candidate, particularly in areas with moderate-to-high malaria transmission. The article also explores key considerations and expectations for RTS,S/AS01 implementation in the wake of WHO’s recommendation of pilot implementation of the vaccine candidate.
Author: Vandoolaeghe P, Schuerman L
» Visit web page (English)
(Located at www.tandfonline.com)
Citation: Vandoolaeghe P, Schuerman L. The RTS,S/AS01 Malaria Vaccine in Children 5 to 17 Months of Age at First Vaccination. Expert Review of Vaccines. 2016;15(12):1481-1493.
Resource types: Peer-reviewed journal